Skip to main content

Advertisement

Table 1 Patient demographics and characteristics at baseline

From: Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

Age, years; mean (SD) 46.8 (10.4)
Female (%) 78.1
Caucasian (%) 86.7
Years since MS diagnosis; mean (SD) 10.6 (7.9)
Number of MS DMTs used prior to natalizumab; mean (SD) 2.0 (1.1)
Proportion of patients treated with 1 DMT prior to natalizumab 35
Proportion of patients treated with ≥ 2 DMTs prior to natalizumab 62
SF-12v2 PCS; mean (SE) 34.2 (0.6)
SF-12v2 MCS; mean (SE) 43.2 (0.7)
Proportion of patients with SF-12v2 PCS ≤ 50a 91
Proportion of patients with SF-12v2 MCS ≤ 50a 69
FS; mean (SD) 2.6 (1.1)b
DS; mean (SD) 2.8 (1.8)c